Arjang Hassibi is the President, Chief Executive Officer, and a board member of InSilixa. He founded InSilixa in 2012 to commercialize the proprietary CMOS biosensor technologies that he had been developing in academia for almost a decade.
Dr. Hassibi’s area of expertise is the intersection of biotechnology and engineering, specifically biosensors and bioelectronics, integrated array technologies, and DNA sequencing. Prior to starting InSilixa, he was a faculty member at the Electrical and Computer Engineering Department and the Institute for Cellular and Molecular Biology of The University of Texas at Austin. During his career, he has held various R&D positions in both industry and academia including Stanford Genome Technology Center, IBM Research at Yorktown, California Institute of Technology (Caltech), and Xagros Genomics, a startup company which he co-founded in 2001. Most recently, he was the Healthcare Thrust Lead at the Silicon Research Corporation (SRC), the world’s leading semiconductor technology research consortium.
Dr. Hassibi received his B.Sc. with the highest honors from the University of Tehran, Iran, and both his M.Sc. and Ph.D. degrees from Stanford University, all in electrical engineering. He attended Caltech for his postdoctoral training. Dr. Hassibi has more than 100 technical publications and patents, almost all in the multidisciplinary area of biosensors and bioelectronics.
Nader Gamini serves as Chief Operating Officer and a board member of InSilixa. He manages manufacturing, finance, corporate development, HR, and legal affairs of InSilixa. In addition, he is responsible for semiconductor packaging design and development, fluidics cartridge design, and instrument development.
Nader has over 30 years of experience in high-volume, global manufacturing of electronics for commercial, military, and medical applications. He has served on the boards of directors of 4 companies, and has been an advisor to many companies in biotech, wireless communications, medical devices, solar, MEMS, optics, and other related industries. Prior to joining InSilixa in 2012, he was the VP of Manufacturing of the PLP Division of NetLogic Microsystem (acquired by Broadcom in 2012). From 2001 to 2007 he was the COO and co-founder of Aeluros (acquired by NetLogic Microsystems in 2007). Before Aeluros he was an executive of several companies with successful exits such as Rambus (IPO in 1997) and Sirenza Microdevices (IPO in 2000).
Nader has a B.Sc. degree in computer science, and dropped out of UCLA’s MBA program to launch his first startup company. He has 9 issued patents in the area of high-performance semiconductor packaging and module technologies.
Gary Schoolnik is the Chief Medical Officer for InSilixa, where he is responsible for matching the unique capabilities of the InSilixa platform with the most important unmet needs in medicine and healthcare. Working with the InSilixa team, he identifies clinical targets, establishes performance metrics, works directly with physician and science leaders in each of the clinical areas and collaborates with regulatory consultants as products move toward FDA submission.
Dr. Schoolnik is also Professor of Medicine, (Emeritus, Active) at Stanford Medical School and Attending Physician in Infectious Diseases and Internal Medicine at Stanford University Hospital. Dr. Schoolnik’s research career has been focused on the use of genomics, molecular biology and biochemistry to elucidate how bacteria cause disease and the use of this information to develop novel diagnostics and to identify drug targets, biomarkers and antigens. His laboratory has performed fundamental studies of uropathogenic and enteropathogenic E. coli, N. gonorrhoeae, V. cholerae and M. tuberculosis, the causative agent of tuberculosis. He is the Principal Investigator of the Gates Foundation funded TBDatabse (TBDB.org), led the multi-institutional NIH funded consortium “TB Systems biology” and was Associate Editor of the Journal of Clinical Investigation and Senior and Founding Editor of Molecular Microbiology. He has published over 200 scientific articles and book chapters and written six issued patents. He serves or has served on a number of advisory boards including the National Advisory Allergy and Infectious Diseases Council which is the principal advisory body of the National Institute of Allergy and Infectious Diseases (NIAID). In addition he served as a sitting member of the FDA Panel on Vaccines and Biologicals.
Dr. Schoolnik received his MD and clinical infectious diseases training at the University of Washington in Seattle, was Intern, Junior, Senior and Chief Resident in Medicine at the Massachusetts General Hospital in Boston and was Research Associate and Senior Physician at the Rockefeller University in Manhatten before joining the Stanford University faculty.
Patrick Grogan is the Sr. VP of Commercial Development for InSilixa, where he is responsible for the development and implementation of the company’s commercial strategy and operations including business development and partnership management.
With over 25 years of executive experience in high growth industry-leading organizations, Patrick, has a proven record of excellence in Strategic Marketing and Corporate Strategic Planning for the Pharma, Biotech, Clinical Diagnostics and Life Science Research markets. Prior to joining InSilixa in January 2015, Patrick was VP of Marketing and Strategic Planning for Becton Dickinson Biosciences where he was responsible for delivering worldwide growth for a $1B life science research and clinical diagnostics business. In this business he was focused on flow cytometry instruments and reagents for Life Science Research, HIV monitoring and Leukemia & Lymphoma worldwide markets in both developed and developing world settings. Prior to that he has held increasingly responsible management positions with Genentech, Parke-Davis/Warner Lambert and Pfizer Inc. As Director of Portfolio Management for Parke Davis and post-acquisition as Sr. Director of Project Management for Pfizer he was responsible for project and portfolio management analysis and recommendations, in collaboration with the WW marketing organization and the project teams, to maximize the value of the drug development portfolio. As a portfolio analyst for the early Genentech organization he performed portfolio and project level financial analysis and reporting to support the rapidly growing drug development portfolio. As a research associate at the University of California, San Francisco he participated in pioneering molecular biology research projects across multiple departments and specialties.
Patrick earned a B.Sc. in biochemistry with first class honors from the National University of Ireland – Galway, and an M.B.A. from the St. Mary’s College, Moraga, CA.
Bob Kuimelis serves as Vice President Chemistry for InSilixa and is responsible for array chemistries from manufacturing to assay, bridging disciplines and technology platform development.
Bob previously held senior management positions at HealthTell, where he built up the technical operations and was responsible for process development of its central high-density peptide microarray platform for early disease detection. As Chemistry Director at Affymetrix for nearly 10 years, he led a department engaged in a range of multidisciplinary R&D programs, new technology development and process transfer & integration. Prior to Affy, he was one of the first to join Phylos (now Adnexus/BMS), a pioneering Boston area startup commercializing directed protein evolution and antibody mimetics. Bob launched his industrial career at Applied Biosystems following a productive postdoctoral stint at Boston College. His interests are at the interface of chemistry, biology and technology and the development of innovative platforms with broad potential to impact health.
Bob received his B.Sc. in Chemistry from Saint Mary’s College of California, and his Ph.D. in Organic Chemistry from the University of California, Davis. He has coauthored 29 scientific publications and holds 27 issued U.S. Patents in the areas of engineered protein scaffolds, nucleic acid chemistry, surface chemistry and microarrays.
Scott Conradson serves as the Senior Vice President of Product Development for InSilixa where he is responsible for integrating InSilixa’s diverse technologies into commercial products and implementing the processes required for regulatory compliance.
Scott has previously held executive R&D, business, and corporate strategy positions at IVD and life science startups and Fortune 1000 companies including Life Technologies, Bio-Rad, Hewlett-Packard, and Complete Genomics. He has led teams developing applications and/or platform products such as: Human Leukocyte Antigen(HLA) DNA sequencing and antibody based assays, DNA sequencer technologies from Sanger through nanopore, protein profiling using MALDI mass spectrometers, flow cytometry, and DNA arrays. Prior to leading product development teams he was a group leader in Hewlett-Packard’s corporate research laboratory doing applied research on leading edge technologies, and was a co-founder of HP’s (now Agilent’s) DNA array business.
Scott received his MS electrical engineering from Santa Clara University and his BS in mechanical engineering from Cal Poly San Luis Obispo with additional work at UCLA and Stanford. Scott has attended Executive Business Programs at Northwestern University and UC Berkeley. He has been an invited speaker at several engineering and IVD conferences, and holds 6 patents in areas ranging from protein identification using charge detection to artificial intelligence applied to computer aided engineering software